| Company/Division name | BD Pharmaceutical Systems |
| Parent company | Becton Dickinson (BD) |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2023 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 70 |
| City reshored to: | Colombus |
| State(s) reshored to: | NE |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | needles, syringes, drug delivery systems |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | , covid-19 |
